Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens
Author:
Affiliation:
1. Department of Clinical Therapeutics; University of Athens; School of Medicine; Athens; Greece
2. Aretaieion Hospital; University of Athens, School of Medicine; Athens; Greece
Publisher
Wiley
Subject
Hematology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.23504/fullpdf
Reference38 articles.
1. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies;Vallet;Expert Opin Pharmacother,2012
2. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma;Dimopoulos;N Engl J Med,2007
3. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America;Weber;N Engl J Med,2007
4. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial;Rajkumar;Lancet Oncol,2010
5. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma;Schey;J Clin Oncol,2004
Cited by 37 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Development and validation of a new risk assessment model for immunomodulatory drug-associated venous thrombosis among Chinese patients with multiple myeloma;Thrombosis Journal;2023-10-04
2. Thrombosis in multiple myeloma: mechanisms, risk assessment and management;Leukemia & Lymphoma;2023-08-16
3. Platelet Parameters as Biomarkers for Thrombosis Risk in Cancer: A Systematic Review and Meta-analysis;Seminars in Thrombosis and Hemostasis;2023-03-15
4. Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma;Cancers;2022-12-16
5. Development and validation of a new risk assessment model for immunomodulatory drug- associated venous thrombosis among Chinese patients with multiple myeloma;2022-10-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3